ACADIA Pharmaceuticals Inc.

NasdaqGS:ACAD 주식 보고서

시가총액: US$2.5b

ACADIA Pharmaceuticals 미래 성장

Future 기준 확인 5/6

ACADIA Pharmaceuticals (는) 각각 연간 41.3% 및 10.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 40% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 30.8% 로 예상됩니다.

주요 정보

41.3%

수익 성장률

40.0%

EPS 성장률

Biotechs 수익 성장27.3%
매출 성장률10.2%
향후 자기자본 수익률30.8%
애널리스트 커버리지

Good

마지막 업데이트22 Oct 2024

최근 미래 성장 업데이트

ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 09
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think

Mar 01
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think

Recent updates

Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again

Aug 26

The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business

Aug 14
The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business

ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 09
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking

Aug 01
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking

Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being

May 23
Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking

Apr 24
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking

We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow

Mar 27
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow

Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue

Mar 12

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think

Mar 01
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think

Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing

Feb 29

Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families

Jan 23

ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Jan 03
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow

Dec 04
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow

Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price

May 22
Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price

Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah

Oct 19

FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide

Sep 12

Acadia: Powerful Unfolding Catalysts

Aug 03

Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome

Jul 18

FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet

Jun 29

수익 및 매출 성장 예측

NasdaqGS:ACAD - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20261,17226429044416
12/31/20251,05315014322419
12/31/20249528513826020
6/30/2024891318081N/A
3/31/2024814-22464N/A
12/31/2023726-61-2317N/A
9/30/2023632-149-133-93N/A
6/30/2023551-111-74-34N/A
3/31/2023520-146-56-56N/A
12/31/2022517-216-114-114N/A
9/30/2022512-217-113-113N/A
6/30/2022512-205-130-130N/A
3/31/2022493-214-142-142N/A
12/31/2021484-168-127-126N/A
9/30/2021474-192-133-130N/A
6/30/2021463-262-141-136N/A
3/31/2021458-260-155-147N/A
12/31/2020442-282-144-136N/A
9/30/2020419-268-144-138N/A
6/30/2020393-225-139-134N/A
3/31/2020366-238-137-136N/A
12/31/2019339-235-152-151N/A
9/30/2019300-248-162-161N/A
6/30/2019264-268-186-184N/A
3/31/2019238-276-189-186N/A
12/31/2018224-245-170-167N/A
9/30/2018208-249-160-158N/A
6/30/2018185-252-175-174N/A
3/31/2018158-256N/A-192N/A
12/31/2017125-289N/A-218N/A
9/30/201793-299N/A-251N/A
6/30/201763-306N/A-242N/A
3/31/201733-309N/A-240N/A
12/31/201617-271N/A-208N/A
9/30/20165-238N/A-182N/A
6/30/20160-206N/A-165N/A
3/31/20160-174N/A-138N/A
12/31/20150-164N/A-122N/A
9/30/20150-147N/A-105N/A
6/30/20150-133N/A-91N/A
3/31/20150-115N/A-78N/A
12/31/20140-92N/A-66N/A
9/30/20140-76N/A-59N/A
6/30/20140-62N/A-51N/A
3/31/20141-50N/A-39N/A
12/31/20131-38N/A-32N/A

애널리스트 미래 성장 예측

수입 대 저축률: ACAD 의 연간 예상 수익 증가율( 41.3% )이 saving rate( 2.5% 보다 높습니다. ).

수익 vs 시장: ACAD 의 연간 수익( 41.3% ) US 시장( 15.4% 보다 빠르게 성장할 것으로 예상됩니다. 15.4% 연간).

고성장 수익: ACAD 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: ACAD 의 수익(연간 10.2% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: ACAD 의 수익(연간 10.2% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: ACAD 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 30.8 %)


성장 기업 발견